S-Adenosyl Methionine in the Therapy of Depression and Other Psychiatric Disorders

Drug Development Research

Volumn 77, Issue 7, 2016, Pages 346-356

  Karas Kuželički, Nataša ^a  

^a UNIVERSITY OF LJUBLJANA   (Slovenia)

Author keywords

Alzheimer's disease; bipolar disorder; depression; S adenosyl methionine; schizophrenia

Indexed keywords

CATECHOL METHYLTRANSFERASE; PHOSPHOLIPID; S ADENOSYLMETHIONINE; HOMOCYSTEINE;

ALZHEIMER DISEASE; ARTICLE; BIPOLAR DISORDER; DEPRESSION; DIARRHEA; DRUG SAFETY; DRUG STABILITY; EPIGENETICS; GENETIC REGULATION; HUMAN; MANIA; MENTAL DISEASE; META ANALYSIS (TOPIC); MULTICENTER STUDY (TOPIC); NAUSEA; NEUROLOGIC DISEASE; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHOSPHOLIPID METHYLATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); SCHIZOPHRENIA; VOMITING; ANIMAL; DNA METHYLATION; GENETIC EPIGENESIS; MENTAL DISORDERS; METABOLISM; METHYLATION; PATHOPHYSIOLOGY; TIME FACTOR;

ANIMALS; DEPRESSION; DNA METHYLATION; EPIGENESIS, GENETIC; HOMOCYSTEINE; HUMANS; MENTAL DISORDERS; METHYLATION; S-ADENOSYLMETHIONINE; TIME FACTORS;

EID: 84992505867     PISSN: 02724391     EISSN: 10982299     Source Type: Journal    
DOI: 10.1002/ddr.21345     Document Type: Article

References (71)

1. Agnoli A, Andreoli V, Casacchia M, Cerbo R. 1976. Effect of s-adenosyl-l-methionine (SAMe) upon depressive symptoms. J Psychiatr Res 13:43–54.
2. AHRQ (Agency for Healthcare Research and Quality) USDfhahs. 2002. S-Adenosyl-L-Methionine for tratment of depression, osteoarthritis, and liver disease. AHFQ Evidence Report 64. http://archive.ahrq.gov/clinic/epcsums/samesum.htm. Retrieved June 1 2016.
3. Barberi A, Pusateri C. 1978. Sugli effetti clinici della s-adenosil-metionina (SAMe) nelle sindromi depressive. Minerva Psichiatr 19:235–244.
4. Bell KM, Plon L, Bunney WE Jr., Potkin SG. 1988. S-adenosylmethionine treatment of depression: a controlled clinical trial. Am J Psychiatry 145:1110–1114.
5. Bell MB, Carreon D, Plon L, Bunney WE, Potkin SG. 1990. Oral s-adenosylmethionine in the treatment of depression: a double-blind comparison with desipramine. Study Report. BioResearch File.
6. Boks MP, de Jong NM, Kas MJ, Vinkers CH, Fernandes C, Kahn RS, Mill J, Ophoff RA. 2012. Current status and future prospects for epigenetic psychopharmacology. Epigenetics 7:20–28.
7. Bortolato B, Miskowiak KW, Kohler CA, Maes M, Fernandes BS, Berk M, Carvalho AF. 2016. Cognitive remission: a novel objective for the treatment of major depression? BMC Med 14:9–26.
8. 12, and S-adenosylmethionine. Psychiatr Clin North Am 36:1–13.
9. Bottiglieri T, Godfrey P, Flynn T, Carney MW, Toone BK, Reynolds EH. 1990. Cerebrospinal fluid S-adenosylmethionine in depression and dementia: effects of treatment with parenteral and oral S-adenosylmethionine. J Neurol Neurosurg Psychiatry 53:1096–1098.
10. Bressa GM. 1994. S-adenosyl-l-methionine (SAMe) as antidepressant: meta-analysis of clinical studies. Acta Neurol Scand Suppl 154:7–14.
11. Carney MW, Edeh J, Bottiglieri T, Reynolds EM, Toone BK. 1986. Affective illness and S-adenosyl methionine: a preliminary report. Clin Neuropharmacol 9:379–385.
12. Caruso I, Fumagalli M, Boccazzini L. 1987. Treatment of depression in rheumatoid arthritic patients. A comaprison of S-adenosylmethionine (Samyr) and placebo in a double-blind study. Clin Trials J 24:305–311.
13. Caruso I, Fumagalli M, Boccassini L, Sarzi Puttini P, Ciniselli G, Cavallari G. 1984. Antidepressant activity of S-adenosylmethionine. Lancet 1:904.
14. Chan A, Remington R, Kotyla E, Lepore A, Zemianek J, Shea TB. 2010. A vitamin/nutriceutical formulation improves memory and cognitive performance in community-dwelling adults without dementia. J Nutr Health Aging 14:224–230.
15. Chitiva H, Audivert F, Alvarez C. 2012. Suicide attempt by self-burning associated with ingestion of S-adenosylmethionine: a review of the literature and case report. J Nerv Ment Dis 200:99–101.
16. Cleare A, Pariante CM, Young AH, Anderson IM, Christmas D, Cowen PJ, Dickens C, Ferrier IN, Geddes J Gilbody S, et al. 2015. Evidence-based guidelines for treating depressive disorders with antidepressants: a revision of the 2008 British Association for Psychopharmacology guidelines. J Psychopharmacol 29:459–525.
17. De Leo D, Serraiotto L, Pellegrini C, Magni G, Franceschi L, Deriu GP. 1987. Outcome from carotid endarterectomy. Neuropsychological performances, depressive symptoms and quality of life: 8-month follow-up. Int J Psychiatry Med 17:317–325.
18. De Vanna M, Rigamonti R. 1992. Oral S-adenosyl-L-Methionine in depression. Curr Ther Res Clin Exp 52:478–486.
19. Deligiannidis KM, Freeman MP. 2014. Complementary and alternative medicine therapies for perinatal depression. Best Pract Res Clin Obstet Gynaecol 28:85–95.
20. Delle Chiaie R, Pancheri P, Scapicchio P. 2002. Efficacy and tolerability of oral and intramuscular S-adenosyl-L-methionine 1,4-butanedisulfonate (SAMe) in the treatment of major depression: comparison with imipramine in 2 multicenter studies. Am J Clin Nutr 76:1172S–1176S.
21. Di Pierro F, Orsi R, Settembre R. 2015. Role of betaine in improving the antidepressant effect of S-adenosyl-methionine in patients with mild-to-moderate depression. J Multidiscip Healthc 8:39–45.
22. Dolcetta D, Parmigiani P, Salmaso L, Bernardelle R, Cesari U, Andrighetto G, Baschirotto G, Nyhan WL, Hladnik U. 2013. Quantitative evaluation of the clinical effects of S-adenosylmethionine on mood and behavior in Lesch-Nyhan patients. Nucleosides Nucleotides Nucleic Acids 32:174–188.
23. Fava M, Rosenbaum JF, Birnbaum R, Kelly K, Otto MW, MacLaughlin R. 1992. The thyrotropin response to thyrotropin-releasing hormone as a predictor of response to treatment in depressed outpatients. Acta Psychiatr Scand 86:42–45.
24. Glick N. 2006. Dramatic reduction in self-injury in Lesch-Nyhan disease following S-adenosylmethionine administration. J Inherit Metab Dis 29:687.
25. Gobejishvili L, Avila DV, Barker DF, Ghare S, Henderson D, Brock GN, Kirpich IA, Joshi-Barve S, Mokshagundam SP McClain CJ, et al. 2011. S-adenosylmethionine decreases lipopolysaccharide-induced phosphodiesterase 4B2 and attenuates tumor necrosis factor expression via cAMP/protein kinase A pathway. J Pharmacol Exp Ther 337:433–443.
26. Goren JL, Stoll AL, Damico KE, Sarmiento IA, Cohen BM. 2004. Bioavailability and lack of toxicity of S-adenosyl-L-methionine (SAMe) in humans. Pharmacotherapy 24:1501–1507.
27. Green T, Steingart L, Frisch A, Zarchi O, Weizman A, Gothelf D. 2012. The feasibility and safety of S-adenosyl-L-methionine (SAMe) for the treatment of neuropsychiatric symptoms in 22q11.2 deletion syndrome: a double-blind placebo-controlled trial. J Neural Transm (Vienna) 119:1417–1423.
28. Guidotti A, Grayson DR, Caruncho HJ. 2016. Epigenetic RELN dysfunction in schizophrenia and related neuropsychiatric disorders. Front Cell Neurosci 10:89.
29. Guidotti A, Ruzicka W, Grayson DR, Veldic M, Pinna G, Davis JM, Costa E. 2007. S-adenosyl methionine and DNA methyltransferase-1 mRNA overexpression in psychosis. Neuroreport 18:57–60.
30. He Q, Xue G, Chen C, Lu ZL, Lei X, Liu Y, Li J, Zhu B, Moyzis RK Dong Q, et al. 2012. COMT Val158Met polymorphism interacts with stressful life events and parental warmth to influence decision making. Sci Rep 2:677.
31. Janicak PG, Lipinski J, Davis JM, Comaty JE, Waternaux C, Cohen B, Altman E, Sharma RP. 1988. S-adenosylmethionine in depression. A literature review and preliminary report. Ala J Med Sci 25:306–313.
32. Kagan BL, Sultzer DL, Rosenlicht N, Gerner RH. 1990. Oral S-adenosylmethionine in depression: a randomized, double-blind, placebo-controlled trial. Am J Psychiatry 147:591–595.
33. King WD, Ho V, Dodds L, Perkins SL, Casson RI, Massey TE. 2012. Relationships among biomarkers of one-carbon metabolism. Mol Biol Rep 39:7805–7812.
34. Lee S, Lemere CA, Frost JL, Shea TB. 2012. Dietary supplementation with S-adenosyl methionine delayed amyloid-beta and tau pathology in 3xTg-AD mice. J Alzheimers Dis 28:423–431.
35. Levkovitz Y, Alpert JE, Brintz CE, Mischoulon D, Papakostas GI. 2012. Effects of S-adenosylmethionine augmentation of serotonin-reuptake inhibitor antidepressants on cognitive symptoms of major depressive disorder. J Affect Disord 136:1174–1178.
36. Loenen WA. 2006. S-adenosylmethionine: jack of all trades and master of everything? Biochem Soc Trans 34:330–333.
37. Maxwell JD, Hunter J, Stewart DA, Ardeman S, Williams R. 1972. Folate deficiency after anticonvulsant drugs: an effect of hepatic enzyme induction? Br Med J 1:297–299.
38. McMullen MH, Rowling MJ, Ozias MK, Schalinske KL. 2002. Activation and induction of glycine N-methyltransferase by retinoids are tissue- and gender-specific. Arch Biochem Biophys 401:73–80.
39. Miccoli L, Porro V, Bertolino A. 1978. Comparison between the antidepressant activity and of S-adenosylmethionine (SAMe) and that of some tricyclic drugs. Acta Neurol (Napoli) 33:243–255.
40. Mischoulon D, Alpert JE, Arning E, Bottiglieri T, Fava M, Papakostas GI. 2012. Bioavailability of S-adenosyl methionine and impact on response in a randomized, double-blind, placebo-controlled trial in major depressive disorder. J Clin Psychiatry 73:843–848.
41. Mischoulon D, Price LH, Carpenter LL, Tyrka AR, Papakostas GI, Baer L, Dording CM, Clain AJ, Durham K Walker R, et al. 2014. A double-blind, randomized, placebo-controlled clinical trial of S-adenosyl-L-methionine (SAMe) versus escitalopram in major depressive disorder. J Clin Psychiatry 75:370–376.
42. Monaco P, Quattrocchi F. 1979. [Study of the antidepressive effects of a biological transmethylating agent (S-adenosyl-methione or SAM)]. Riv Neurol 49:417–439.
43. Morrison LD, Smith DD, Kish SJ. 1996. Brain S-adenosylmethionine levels are severely decreased in Alzheimer's disease. J Neurochem 67:1328–1331.
44. Murphy BL, Babb SM, Ravichandran C, Cohen BM. 2014. Oral SAMe in persistent treatment-refractory bipolar depression: a double-blind, randomized clinical trial. J Clin Psychopharmacol 34:413–416.
45. Muscettola G, Galzenati M, Balbi A. 1982. SAMe versus placebo: a double blind comparison in major depressive disorders. Adv Biochem Psychopharmacol 32:151–156.
46. Oscarsson J, Gardmo C, Eden S, Mode A. 2001. Pulsatile growth hormone secretion decreases S-adenosylmethionine synthetase in rat liver. Am J Physiol Endocrinol Metab 280:E280–E286.
47. Pace TW, Miller AH. 2009. Cytokines and glucocorticoid receptor signaling. Relevance to major depression. Ann N Y Acad Sci 1179:86–105.
48. Papakostas GI, Alpert JE, Fava M. 2003. S-adenosyl-methionine in depression: a comprehensive review of the literature. Curr Psychiatry Rep 5:460–466.
49. Papakostas GI, Mischoulon D, Shyu I, Alpert JE, Fava M. 2010. S-adenosyl methionine (SAMe) augmentation of serotonin reuptake inhibitors for antidepressant nonresponders with major depressive disorder: a double-blind, randomized clinical trial. Am J Psychiatry 167:942–948.
50. Peedicayil J. 2012. Role of epigenetics in pharmacotherapy, psychotherapy and nutritional management of mental disorders. J Clin Pharm Ther 37:499–501.
51. Pfalzer AC, Choi SW, Tammen SA, Park LK, Bottiglieri T, Parnell LD, Lamon-Fava S. 2014. S-adenosylmethionine mediates inhibition of inflammatory response and changes in DNA methylation in human macrophages. Physiol Genomics 46:617–623.
52. Remington R, Bechtel C, Larsen D, Samar A, Doshanjh L, Fishman P, Luo Y, Smyers K, Page R Morrell C, et al. 2015. A phase II randomized clinical trial of a nutritional formulation for cognition and mood in Alzheimer's disease. J Alzheimers Dis 45:395–405.
53. Salmaggi P, Bressa GM, Nicchia G, Coniglio M, La Greca P, Le Grazie C. 1993. Double-blind, placebo-controlled study of S-adenosyl-L-methionine in depressed postmenopausal women. Psychother Psychosom 59:34–40.
54. Sarris J, Murphy J, Mischoulon D, Papakostas GI, Fava M, Berk M, Ng CH. 2016. Adjunctive nutraceuticals for depression: a systematic review and meta-analyses. Am J Psychiatry 173:575–587.
55. Sarris J, Papakostas GI, Vitolo O, Fava M, Mischoulon D. 2014. S-adenosyl methionine (SAMe) versus escitalopram and placebo in major depression RCT: efficacy and effects of histamine and carnitine as moderators of response. J Affect Disord 164:76–81.
56. Sarris J, Price LH, Carpenter LL, Tyrka AR, Ng CH, Papakostas GI, Jaeger A, Fava M, Mischoulon D. 2015. Is S-adenosyl methionine (SAMe) for depression only effective in males? a re-analysis of data from a randomized clinical trial. Pharmacopsychiatry 48:141–144.
57. Scarzella R, Appiotti A. 1978. Confronto clinico in doppio cieco della SAMe versus clorimipramina nelle sindromi depressive. Rivisita Sperimentale Di Feniatria 102:359–366.
58. Schaller JL, Thomas J, Bazzan AJ. 2004. SAMe use in children and adolescents. Eur Child Adolesc Psychiatry 13:332–334.
59. Schrotter A, Pfeiffer K, El Magraoui F, Platta HW, Erdmann R, Meyer HE, Egensperger R, Marcus K, Muller T. 2012. The amyloid precursor protein (APP) family members are key players in S-adenosylmethionine formation by MAT2A and modify BACE1 and PSEN1 gene expression-relevance for Alzheimer's disease. Mol Cell Proteomics 11:1274–1288.
60. Selley ML. 2007. A metabolic link between S-adenosylhomocysteine and polyunsaturated fatty acid metabolism in Alzheimer's disease. Neurobiol Aging 28:1834–1839.
61. Shea TB, Chan A. 2008. S-adenosyl methionine: a natural therapeutic agent effective against multiple hallmarks and risk factors associated with Alzheimer's disease. J Alzheimers Dis 13:67–70.
62. Strous RD, Ritsner MS, Adler S, Ratner Y, Maayan R, Kotler M, Lachman H, Weizman A. 2009. Improvement of aggressive behavior and quality of life impairment following S-adenosyl-methionine (SAM-e) augmentation in schizophrenia. Eur Neuropsychopharmacol 19:14–22.
63. Thomas CS, Bottiglieri T, Edeh J, Carney MW, Reynolds EH, Toone BK. 1987. The influence of S-adenosylmethionine (SAM) on prolactin in depressed patients. Int Clin Psychopharmacol 2:97–102.
64. Thompson MA, Bauer BA, Loehrer LL, Cha SS, Mandrekar JN, Sood A, Wahner-Roedler DL. 2009. Dietary supplement S-adenosyl-L-methionine (AdoMet) effects on plasma homocysteine levels in healthy human subjects: a double-blind, placebo-controlled, randomized clinical trial. J Altern Complement Med 15:523–529.
65. Tiemeier H, van Tuijl HR, Hofman A, Meijer J, Kiliaan AJ, Breteler MM. 2002. Vitamin B12, folate, and homocysteine in depression: the Rotterdam Study. Am J Psychiatry 159:2099–2101.
66. Trivedi MS, Deth RC. 2012. Role of a redox-based methylation switch in mRNA life cycle (pre- and post-transcriptional maturation) and protein turnover: implications in neurological disorders. Front Neurosci 6:92.
67. Tsao D, Diatchenko L, Dokholyan NV. 2011. Structural mechanism of S-adenosyl methionine binding to catechol O-methyltransferase. PLoS One 6:e24287.
68. Tsao D, Wieskopf JS, Rashid N, Sorge RE, Redler RL, Segall SK, Mogil JS, Maixner W, Dokholyan NV, Diatchenko L. 2012. Serotonin-induced hypersensitivity via inhibition of catechol O-methyltransferase activity. Mol Pain 8:25.
69. Turner P, Kantaria R, Young AH. 2014. A systematic review and meta-analysis of the evidence base for add-on treatment for patients with major depressive disorder who have not responded to antidepressant treatment: a European perspective. J Psychopharmacol 28:85–98.
70. Watanabe K, Kakeda S, Yoshimura R, Abe O, Ide S, Hayashi K, Katsuki A, Umene-Nakano W, Watanabe R Nakamura J, et al. 2015. Relationship between the catechol-O-methyl transferase Val108/158Met genotype and brain volume in treatment-naive major depressive disorder: voxel-based morphometry analysis. Psychiatry Res 233:481–487.
71. Yang CP, Wang HA, Tsai TH, Fan A, Hsu CL, Chen CJ, Hong CJ, Chen YM. 2012. Characterization of the neuropsychological phenotype of glycine N-methyltransferase-/- mice and evaluation of its responses to clozapine and sarcosine treatments. Eur Neuropsychopharmacol 22:596–606.